[HTML][HTML] EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy

YH Kim, K Masago, Y Togashi… - Oncology …, 2011 - spandidos-publications.com
Somatic mutations of epidermal growth factor receptor (EGFR) are the strongest predictive
markers for the response to EGFR-tyrosine kinase inhibitors (TKIs). Patients with EGFR …

EGFR mutations as a predictive marker of cytotoxic chemotherapy

JH Park, SH Lee, B Keam, TM Kim, DW Kim, SC Yang… - Lung Cancer, 2012 - Elsevier
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are important predictive markers for the response to EGFR-tyrosine kinase …

[HTML][HTML] Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated …

M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

JY Lee, SH Lim, M Kim, S Kim, HA Jung… - Cancer chemotherapy …, 2014 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …

[HTML][HTML] Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine …

SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation

M Wen, J Xia, Y Sun, X Wang, X Fu… - … : Targets and Therapy, 2018 - Taylor & Francis
Purpose Both epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer …

Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer

J Fukihara, N Watanabe, H Taniguchi, Y Kondoh… - Oncology, 2014 - karger.com
Background: The presence of EGFR (epidermal growth factor receptor) mutations is a robust
predictor of EGFR tyrosine kinase inhibitor (TKI) responsiveness. Predictors of EGFR-TKI …

Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis

H Wang, M Zhang, W Tang, J Ma, B Wei… - Cancer Biology & …, 2018 - Taylor & Francis
Purpose: To investigate the influence of mutation abundance and sites of epidermal growth
factor receptor (EGFR) on therapeutic efficacies of EGFR-tyrosine kinase inhibitor (EGFR …

Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis

L Paz‐Ares, D Soulières, I Melezínek… - Journal of cellular …, 2010 - Wiley Online Library
Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

[HTML][HTML] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …

W Liang, Y Zhang, S Kang, H Pan, W Shao… - Journal of Thoracic …, 2014 - ncbi.nlm.nih.gov
Objectives Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …